Epithelial Ovarian Cancer
220
40
56
80
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
41 trials with published results (19%)
Research Maturity
80 completed trials (36% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
12.7%
28 terminated out of 220 trials
74.1%
-12.5% vs benchmark
14%
30 trials in Phase 3/4
51%
41 of 80 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 80 completed trials
Clinical Trials (220)
A Study of Isoquercetin in People With Ovarian Cancer
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Centralization and Oncologic Outcomes in Ovarian Cancer
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a Prospective Multicenter Randomized Trial
Genomic BRCA and Extensive ovArian Cancer Testing
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors